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Assay of FK 506 in Plasma 
E.M. Cadott. R. Venkataramanan. A. Krajack. A.S. Jain. J.J. Fung, S. Todo. and T.E. Starzl 
FK 506 is a potent immunosuppressive agent in vitro 
and in vivo in animals and. as discussed extensively 
in this symposium. in humans. In contrast to the early use 
of Cy A. an assay for the measurement of FK 506 has been 
available for use in these early studies. I We present our 
experience with the modified enzyme immunoassay (ElA) 
procedure we have used in preciinical studies and in the 
early clinical trials of FK 506. 
MATERIALS AND METHODS 
FK 506 Assay 
The FK 506 assay IS an EIA using a mouse monoclonal anll-fK 
506 antlbodv (Fujisawa Pharmaceuticals Co Ltd. Osaka. Japan,. 
Briefiy. anu-mouse 19G is adsorbed onto a 96-well fiat·bottomed 
microliter plate (Row Labs. Mclean. V A I overnIght at 4·C and 
the plate is blocked with 0.5% albUmin. fK S06 Ifujisawa' 
standards (a zero standard and from 0.1 to 5.0 ng/mil are prepared 
lOx concentrated in methanol (MeOH). One hundred microliters 
of plasma is pretreated with I ml of 0.1 N HCl. and 100 IIol of FK 
506-free plasma is used for the standards. Ten microliters of 
standard solution or MeOH blank is then added to each sample. 
One milliliter of the treated sample IS loaded onto a C·18 minI-
column (Sep-pak. Waters. Milford. MAl that has been prewet 
wllh MeOH and acetic acid. The samples are washed with acetic 
acid and eluted wllh 3.0 ml of MeOH. The eluate IS evaporated to 
dryness and reconstituted with peroxidase labeled FK 506 (Fuji-
,awal. Reconstituted sample and monoclonal antibody are placed 
10 each well. and competitive binding occurs overnIght a14"C with 
gentie agitation. Unbound FK S06 is removed. and the acuvity of 
the bound FK 506-peroxidase conjugate IS measured by Ihe 
Increase in opllcal density (00) at 492 nm aiter a lO-mlnute 
iOcubauon with o-phenylenediamine ISigma. Sl Louis. MO) sub-
strate. 
The standard cUn'e is lineanzcd uSing a 10g·IClglt transfonna-
lion. and controls and unknowns are calculated from the regres-
sion Ime. 
PrectSlon. Accuracv. and Recovery Studies 
Pools of human plasma were spiked with FK S06 10 concentra-
tions of O.S. 1.0. and 2.0 ng/ml. Aliquots of these samples were 
taken with each run to detenmne accuracy and precIsion. Recov-
.:ry of the extnlCtion procedure was assessed by diluting 10 IAl of 
the standards to 3 ml in MeOH and processing !.hem further as 
mlru-column eluates. 
Interference 
Samples with a vanety of bilirubin and fK S06 concentrations 
were preparet1 using normal plasma and plasma irom a JauOluced 
paltent not on FK 506: the plasma was spIked wllh FK 506. A 
sirrular matrut was created with plasma contaminated with hemo-
I yzed red blood cells. FK S06 was measured In samples sent ior 
CyA deterrrunatlon to look for cross·reactlVltv. 
Separation of Plasma 
Whole blood samples from patients on FK 506 are mixed thor-
oughly and divided into two aliquOlS. One is left at room temper-
ature and centrifuged. the second is incubated at 37"C for a 
minimum of 30 minutes. then spun at 31'C. Plasma from both 
aliquots is stored at 4"C until assayed. 
RESULTS 
FK 506 Enzyme Immunoassay 
Measurements of 00 vary considerably from day to day, 
with the zero standard ranging from 0.8 to 2.0. However. 
the variation is consistent within each run. The coefficient 
of variation (CY) of the FK 506 assay is 27% at 0.5 ng/Illi. 
23% at 1.0 ng/ml. and 15% at 2.0 ng/ml. The assayed values 
of these samples are 0.47. 0.93. and 2.1 ng/ml. respec-
tively, with accuracies thus ranging from 93% to 95%. The 
recovery of the extraction ranges from 100% at 0.5 nglllli to 
125% at 5.0 ng/mi. The linear range is 0.1 to 5.0 ng/mi. 
Samples with higher concentration are diluted with FK 
5()6.free plasma. 
Interference Studies 
Hemolysis does not interfere with the FK 506 assay. even 
when marked hemolysis is present. A low FK 506 concen-
tration sample measured 0.1. O. I. and < 0.1 ng/m1 when 
slight. moderate. or marked hemolysis was present. An-
other measured 0.5.0.3. and 0.3. respectively, and a third 
measured 1.1. 1.0. and 1.2. Similarly. at bilirubin concen-
trations of 10. 160. and 310 ~osi (0.5.9. and 18 mg/d1). 
F_K 506 measured < 0.1. < 0.1. < 0.1. respectively. in one 
sample. 0.5. 0.4. and 0.4 in a second. and 1.7. 1.7. and 1.9 
in a third. Cy A concentrations of up to 2.000 ng/m1 by 
FPIA (TOxlt) did not cross-react in the FK 506 assay. 
reading< 0.1 ng/m1 FK 506. 
Plasma SeparatIOn 
For 220 samples from eight patients. separation of plasma 
at both room temperature and-at 37"C was done. Plasma 
separated at room temperature contained <75% of the 
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amount of FK 506 compared with its 31'C aliquot (room 
temperature = 0.75 x [31'C1 - 0.2: r = 0.9763). 
Dose Response 
In 30 patients. the relationship between dose of FK 506 
and 12-hour trough concentrations was studied with a 
correlation coefficient of r < 0.3. To eliminate the interpa-
tient vanability. one patient was identified in whom an 
intrapatient dose-response curve could be examined. Re-
gression revealed a correlation coefficient of r < 0.33 in 
this patient. 
DISCUSSION 
The FK 506 assay has performed satisfactonly in our 
laboratory. Measurement of FK 506 concentrations in 
animal studies has shown wide imerspecles variation in 
kinetics'; and dosing requirements.J and in vitro studies 
have shown interspecies variations in sensitivity of lym-
phocytes to FK 506." It was therefore felt that the assay 
5 ystem would be necessary for adjusting dosing and deter· 
mining pharmacokinetics in phase I clinical trials. 
Although the 00 varies from day to day. we were 
unable to discern either a consistent pattern or the reason 
for this variation. Despite this effect. the shape of the 
standard curve is uniform each day. and results of the 
control samples are consistent. The 15-27% CV compares 
reasonably with that of CyA~ur current CyA high-
pressure liquid chromatography assay has a CV of 14-22% 
and our radioimmunoassay has a CV of 10-19%. Automa-
tion of CyA for the TDxB. has improved the CV to 7-14%. 
Two major factors accounting for the lesser precision of 
the FK 506 assay are the low concentrations of the agent 
and the inexactness of an EIA. The calculated accuracy 
and recovenes are not significantly different from 100%. 
Since FK 506 kinetics dilfer in pauents with liver 
failure'! it was essential to demonstrate that this is not due 
51 
to bilirubin interfering with the assay. Similarly. FK 506 
measurements on hemolyzed samples are accurate. 
Initial pharmacokinetic studies in humans and expen-
ence with Cy A have suggested that the distribution of FK 
506 between red blood cells and plasma may be tempera-
ture-dependent. Indeed. we did find such a temperature 
dependence and have switched to 31'C separatiort-to 
reflect in vivo conditions. This has allowed for reliable 
studies on the distribution and elimination of FK 506.6 
The poor correlation between dose and plasma concen-
tration of FK 506 is similar to that seen in baboons. J 
However. the safety and efficacy profile seen in the phase 
I clinical trials may obviate the need for precise and 
frequent measurement of FK 506 to fine-tune plasma 
concentrations. 1·9 
The current FK 506 assay has been essential to the 
preclinical and early clinical trials of FK 506. and measure-
ment of FK 506 will be necessary as clinical trials con-
tinue. Measurement of FK 506 concentrations will be 
necessary early in therapy, especially for patients with 
liver failure. but routine "FK 506 levels" may not be 
needed as frequently as they are for Cy A. 
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